SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Phase II, randomized, double-blind, placebo-controlled study to evaluate the treatment
effects and safety of SLS-005 in Participants with Alzheimer's Disease (AD) treated weekly
for 52 weeks.